Alexion, AstraZeneca Rare Disease at ASHG 2026

Oct 20–24, 2026 Montréal, Canada ~7.5k attendees Website

Alexion, AstraZeneca Rare Disease at ASHG 2026 in Montréal: 1 presentation (1 poster).

Organization	ASHG 2026 Attendance
Alexion, AstraZeneca Rare Disease Boston, Massachusetts	1 AI Lead & Strategy Advisor
alexion.com\|LinkedIn Subsidiary Alexion develops and commercializes prescription medicines for patients and families affected by rare diseases. Its portfolio spans complement-mediated, metabolic and neurologic conditions. Is using AI partnerships and its own innovations to try to shorten the diagnostic odyssey for rare-disease patients. › Is using AI partnerships and its own innovations to try to shorten the diagnostic odyssey for rare-disease patients. 2026-08 · source Is pursuing new modalities, including engineered nanobodies and RNA-based therapies, to advance complement-inhibition science. 2026-08 · source Says it is applying genomic insights to deepen understanding of rare diseases and advance genomic medicines. 2026-07 · source Source: company newsroom Parent AZ Rare Disease revenue $4.9B in H1 2026, up 11% › Figures are for the AstraZeneca Rare Disease unit overall, part of AstraZeneca's larger, reaffirmed full-year guidance. · 2026-07-27 “Total Revenue \| 30,672 \| 9 \| 6 \| 15,384 \| 6 \| 5; At CER, Total Revenue is expected to increase by a mid-to-high single-digit % and Core EPS by a low double-digit %.” Source: results release Currently hiring: 130 open roles › Source: careers page	Poster Fri Oct 23 2:30 pm ★ Reviewers’ Choice Part of Molecular Effects of Genetic Variation Poster Friday Session Comprehensive functional characterization of missense variants in the Hypophosphatasia causal gene ALPL Exhibit & Poster Hall · Board 6015F Variant interpretationRare variantsClinical geneticsDiagnostics

Organization

ASHG 2026 Attendance

Alexion, AstraZeneca Rare Disease

Boston, Massachusetts

1 AI Lead & Strategy Advisor

alexion.com|LinkedIn

Subsidiary

Alexion develops and commercializes prescription medicines for patients and families affected by rare diseases. Its portfolio spans complement-mediated, metabolic and neurologic conditions.

Is using AI partnerships and its own innovations to try to shorten the diagnostic odyssey for rare-disease patients.

›

Is using AI partnerships and its own innovations to try to shorten the diagnostic odyssey for rare-disease patients.

2026-08 · source

Is pursuing new modalities, including engineered nanobodies and RNA-based therapies, to advance complement-inhibition science.

2026-08 · source

Says it is applying genomic insights to deepen understanding of rare diseases and advance genomic medicines.

2026-07 · source

Source: company newsroom

Parent AZ Rare Disease revenue $4.9B in H1 2026, up 11%

›

Figures are for the AstraZeneca Rare Disease unit overall, part of AstraZeneca's larger, reaffirmed full-year guidance. · 2026-07-27

“Total Revenue | 30,672 | 9 | 6 | 15,384 | 6 | 5; At CER, Total Revenue is expected to increase by a mid-to-high single-digit % and Core EPS by a low double-digit %.”

Source: results release

Currently hiring: 130 open roles

›

Source: careers page

Poster

Fri Oct 23
2:30 pm

★ Reviewers’ Choice

Part of Molecular Effects of Genetic Variation Poster Friday Session

Comprehensive functional characterization of missense variants in the Hypophosphatasia causal gene ALPL

Exhibit & Poster Hall · Board 6015F

Variant interpretationRare variantsClinical geneticsDiagnostics